Attention Deficit Disorder
Atomoxetine approved to treat attention deficit/hyperactivity disorder
Published in Medical Letter on the CDC and FDA, January 16th, 2005
According to recent research published in the journal Fortschritte der Neurologie Psychiatrie, "Atomoxetine is a selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD). In vitro, ex vivo, and in vivo studies have shown that atomoxetine is a highly selective antagonist of the presynaptic norepinephrine transporter with little or no affinity for other noradrenergic receptors or other neurotransmitter transporters or receptors. So far, two open-label and seven randomized, double-blind,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Anthrax Pathogenesis
Cytokine response to infection with Bacillus anthracis spores described - Antimicrobials
New regulatory approaches to antimicrobial safety developed - Drug Resistance
Anti-microbial use in animals linked to resistance in bacteria in humans - Enterovirus
Two proposed new enterovirus serotypes, EV74 and EV75, characterized - Hepatitis E Virus
Kyrgyzstan swine hepatitis E virus sequenced - Adverse Drug Events
Potentially fatal toxicities occur with off-label use of cancer drugs - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
